Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary.

Ball SG, Desaiah D, Zhang Q, Thase ME, Perahia DG.

Drugs Context. 2013 Jan 3;2013:212245. doi: 10.7573/dic.212245. eCollection 2013 Jan 3. Review.

2.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
3.

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1849-58. doi: 10.1185/03007995.2011.609539. Epub 2011 Aug 12.

PMID:
21838411
4.

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K.

J Clin Psychiatry. 2007 Nov;68(11):1707-16.

PMID:
18052564
5.

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1859-67. doi: 10.1185/03007995.2011.609540. Epub 2011 Aug 12.

PMID:
21838410
6.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM.

J Psychiatr Res. 2006 Jun;40(4):337-48. Epub 2005 Nov 4.

PMID:
16271726
7.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
8.

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA.

J Clin Psychiatry. 2002 Apr;63(4):308-15.

PMID:
12000204
9.
10.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.

Eur Psychiatry. 2006 Sep;21(6):367-78. Epub 2006 May 11.

PMID:
16697153
11.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

OliƩ JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. French.

PMID:
20004291
12.

Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine.

Tokuoka H, Nishihara M, Fujikoshi S, Yoshikawa A, Kuga A.

Neuropsychiatr Dis Treat. 2017 Sep 25;13:2457-2467. doi: 10.2147/NDT.S143093. eCollection 2017.

14.

Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.

Bailey RK, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM.

J Natl Med Assoc. 2006 Mar;98(3):437-47.

15.

Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.

Cowen PJ, Ogilvie AD, Gama J.

Curr Med Res Opin. 2005 Mar;21(3):345-56. Review.

PMID:
15811202
16.

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA.

J Psychiatr Res. 2002 Nov-Dec;36(6):383-90.

PMID:
12393307
17.

Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials.

Ball SG, Desaiah D, Spann ME, Zhang Q, Russell JM, Robinson MJ, Demyttenaere K.

Prim Care Companion CNS Disord. 2011;13(6). pii: PCC.11r01181. doi: 10.4088/PCC.11r01181.

18.

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.

Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.

Psychopharmacology (Berl). 2015 Jun;232(12):2061-70. doi: 10.1007/s00213-014-3839-0. Epub 2015 Jan 11.

19.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
20.

Duloxetine in the treatment of major depressive disorder: an open-label study.

Hudson JI, Perahia DG, Gilaberte I, Wang F, Watkin JG, Detke MJ.

BMC Psychiatry. 2007 Aug 28;7:43.

Supplemental Content

Support Center